We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$12.1B
AUM Growth
+$1.27B
Cap. Flow
+$1.03B
Cap. Flow %
8.56%
Top 10 Hldgs %
10.66%
Holding
624
New
180
Increased
169
Reduced
84
Closed
163

Sector Composition

Rank Sector Weight
1 Technology 15.27%
2 Industrials 13.28%
3 Healthcare 12.87%
4 Consumer Discretionary 10.6%
5 Consumer Staples 10.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GNCA
426
DELISTED
Genocea Biosciences, Inc.
GNCA
$929K 0.01%
28,196
+225
+0.8% +$7.41K
IMDZ
427
DELISTED
Immune Design Corp.
IMDZ
$921K 0.01%
167,493
+1,334
+0.8% +$9.42K
NVCN
428
DELISTED
Neovasc Inc.
NVCN
$888K 0.01%
21
+1
+5% +$24K
IVTY
429
DELISTED
Invuity, Inc
IVTY
$856K 0.01%
+148,800
New +$1.24M
ATXS
430
DELISTED
Astria Therapeutics
ATXS
$808K 0.01%
3,731
+444
+14% +$109K
GHL
431
DELISTED
Greenhill & Co., Inc.
GHL
$778K 0.01%
+28,082
New +$724K
PTN
432
CALL
Palatin Technologies
PTN
$13.8M
$777K 0.01%
+1,231
New +$857K
BIOA
433
CALL
DELISTED
BioAmber Inc.
BIOA
$746K 0.01%
135,648
+1,080
+0.8% +$5.18K
ASAP
434
CALL
DELISTED
Waitr Holdings Inc. Common Stock
ASAP
$700K 0.01%
50,000
ELF icon
435
e.l.f. Beauty
ELF
$5.81B
$695K 0.01%
24,000
-78,135
-77% -$2.21M
BLD
436
DELISTED
TopBuild
BLD
$663K 0.01%
18,625
-17,309
-48% -$596K
TBCH
437
Turtle Beach Corp
TBCH
$277M
$655K 0.01%
125,000
-87,500
-41% -$495K
AKAO
438
DELISTED
Achaogen Inc
AKAO
$651K 0.01%
+50,000
New +$343K
ARCC icon
439
Ares Capital
ARCC
$14.4B
$634K 0.01%
+38,448
New +$605K
QLYS icon
440
Qualys
QLYS
$6.35B
$593K ﹤0.01%
18,727
-1,062,712
-98% -$37.4M
BLRX
441
BioLineRX
BLRX
$11.8M
$591K ﹤0.01%
1,071
+9
+0.8% +$5.59K
WINT
442
DELISTED
Windtree Therapeutics Inc
WINT
$581K ﹤0.01%
464,769
+3,703
+0.8% +$6.84K
INNL
443
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$578K ﹤0.01%
837,626
+305,482
+57% +$1.13M
SYRE icon
444
Spyre Therapeutics
SYRE
$9.25B
$521K ﹤0.01%
4,788
+402
+9% +$58.6K
BLVD
445
CALL
DELISTED
Boulevard Acquisition Corp. II Class A Common Stock
BLVD
$501K ﹤0.01%
945,134
TCON
446
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$490K ﹤0.01%
+500
New +$571K
CST
447
DELISTED
CST Brands, Inc.
CST
$489K ﹤0.01%
+10,152
New +$488K
NTBL
448
CALL
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$404K ﹤0.01%
2,381
LINC icon
449
Lincoln Educational Services
LINC
$1.3B
$376K ﹤0.01%
+195,644
New +$372K
ENSV
450
DELISTED
Enservco Corp.
ENSV
$369K ﹤0.01%
+43,914
New +$367K

Similar funds

Alyeska Investment Group's Q4 2016 Portfolio in Review

As of Q4 2016, Alyeska Investment Group held 624 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Alyeska Investment Group deployed $1.03B of net new capital in Q4 2016, opening 180 new positions and adding to 169 existing holdings. Its largest new stake was Texas Instruments: 1,378,860 shares worth $101M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Palo Alto Networks, an estimated $120M trimmed.

  • Alyeska Investment Group's largest Q4 2016 buy was Texas Instruments: 1,378,860 shares worth $101M.
  • Alyeska Investment Group added most to Alphabet (Google) Class A in Q4 2016, an estimated $135M increase.
  • Alyeska Investment Group's biggest Q4 2016 reduction was Palo Alto Networks, cutting an estimated $120M.
  • Alyeska Investment Group fully exited Apple in Q4 2016, selling an estimated $217M.
  • Alyeska Investment Group's ten largest holdings make up 11% of its $12.1B portfolio in Q4 2016.
  • Alyeska Investment Group opened 180 new positions and closed 163 in Q4 2016.
  • Alyeska Investment Group's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.